The arrest review of former Kolon Group chairman Woong-Yeol Lee, who is considered as the final head of suspicion surrounding Invosakei (Invossa), an osteoarthritis treatment, was postponed to tomorrow (30th).

Deputy Judge Kim Dong-hyun of the Seoul Central District Court decided to hold the warrant review of the former chairman, who was scheduled for 9:30 am today, at the same time tomorrow.

The reason for this is that former chairman Lee requested the prosecution to postpone the review because of the sudden arrest time for urgent arrest.

It is expected that Lee's arrest will be decided later in the afternoon.

Earlier, the Seoul Central District Attorney Criminal Division 2 (Lee Chang-soo, Assistant Prosecutor) filed for a warrant for arrest on the 25th for alleged violations of the Pharmacopoeia Act, fraud, fraudulent transactions in the Capital Markets Act, market manipulation, and reimbursement.

Chairman Lee, from November 2017 to March of last year, received the approval of an item of'cartilage cell' for 2 components of Invossa from the Ministry of Food and Drug Safety, but the contents of the'kidney-derived cell (GP2-293)' differ from the permission. They are charged with manufacturing and selling.

Even if you know that it contains kidney-derived cells, not chondrocytes, you are also accused of hiding them and submitting false data to obtain permission from the Food and Drug Administration.

The prosecution also reported that former chairman Lee was also involved in Kolon Tissuezine's'listed fraud', and also applied charges of fraudulent trading and market manipulation under the Capital Markets Act.

The prosecution plans to finalize the investigation that has been underway for more than a year when Lee's decision to deal with recruits is over.

The prosecution began investigations in June last year, accusing the Ministry of Food and Drug Safety, and passed six cases, including Lee Woo-suk (63), CEO of Kolon Life Science and Kolon Tissue Gene Corporation.